Immune checkpoint inhibitors combined with platinum-based doublet chemotherapy have become standard first-line treatment for HER2-negative advanced GC (Janjigian et al., 2021; Rha et al., 2023; Kang et al., 2022; Shitara et al., 2020a). The gene discussed is ERBB2; the disease is gastric cancer.